Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 350Polycystic Ovary Syndrome 39Endometrial Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 16Infertility 12Neoplasms 11Fallopian Tube Neoplasms 8Advanced Breast Cancer 8Triple Negative Breast Neoplasms 7Carcinoma, Intraductal, Noninfiltrating 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Recurrence 6Osteoporosis 6Carcinoma, Lobular 6Breast Diseases 6Breast Carcinoma In Situ 6Prostatic Neoplasms 5Leiomyoma 4Infertility, Female 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Neoplasms, Hormone-Dependent 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Anovulation 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2

Interventions

camrelizumab 1Surgical Procedures, Operative 1Paclitaxel 1ON123300 1Letrozole 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endometrioid Endometrial Cancer × Letrozole × Clear all
NCT05705505 2023-12-12

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Traws Pharma, Inc.

Phase 1/2 Unknown
60 enrolled
Gynecologic

Endometrioid Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡